• 2026.02.28
    三种铜肽类原料核心差异及原料一注射安全风险解析 三种铜肽类原料核心差异及原料一注射安全风险解析

    本文针对三种名称相近的铜肽类原料,从化学特性、核心结构、功效定位及应用场景进行专业解析,明确三者本质区别;同时结合业务实操,重点说明原料一(CAS 49557-75-7)作为注射原料的安全风险,为原料采购、配方研发、客户对接及合规管控提供科学参考,适配海外业务需求。​

    了解更多
  • 2026.02.27
    The Evolution of Unimolecular Polypharmacy: Decoding the Synthetic and Clinical Superiority of UBT251 The Evolution of Unimolecular Polypharmacy: Decoding the Synthetic and Clinical Superiority of UBT251

    The metabolic therapeutic landscape is shifting from simple peptide analogs to Unimolecular Polypharmacy. While GLP-1 mono-agonists (e.g., Semaglutide) have revolutionized obesity care, the recent 19.7% weight reduction observed in the China Phase II trial of UBT251 represents a quantum leap. This triple agonist doesn't just iterate; it redefines the pharmacological ceiling for non-surgical weight loss.

    了解更多
  • 2026.02.27
    Copper Tripeptide-1 (GHK-Cu) (CAS: 49557-75-7) Copper Tripeptide-1 (GHK-Cu) (CAS: 49557-75-7)

    Discover Copper Tripeptide-1 (GHK-Cu) CAS 49557-75-7, the science-backed skin repair & anti-aging peptide for cosmetic formulations. Learn its molecular profile, core efficacy, recommended dosage and application guidelines for skincare R&D.

    了解更多